RO7268489
Sponsors
F. Hoffmann-La Roche AG, Hoffmann-La Roche
Conditions
Progressive Forms of Multiple Sclerosis (PMS)Progressive Multiple Sclerosis
Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
RecruitingNCT07282574
Start: 2026-03-10End: 2030-05-30Target: 360Updated: 2026-08-17
A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis
Not yet recruitingCTIS2025-521636-10-00
Target: 220Updated: 2026-01-30